Public Act 100-0799
 
SB2889 EnrolledLRB100 19109 MJP 34369 b


  
    AN ACT concerning health.
  
 
    Be it enacted by the People of the State of Illinois,
 
represented in the General Assembly:
  


 
    Section 5. The School Code is amended by changing Section 
22-30 as follows:
 


    (105 ILCS 5/22-30)




    Sec. 22-30. Self-administration and self-carry of asthma 
medication and epinephrine injectors auto-injectors; 
administration of undesignated epinephrine injectors 
auto-injectors; administration of an opioid antagonist; asthma 
episode emergency response protocol.

    (a) For the purpose of this Section only, the following 
terms shall have the meanings set forth below:

    "Asthma action plan" means a written plan developed with a 
pupil's medical provider to help control the pupil's asthma. 
The goal of an asthma action plan is to reduce or prevent 
flare-ups and emergency department visits through day-to-day 
management and to serve as a student-specific document to be 
referenced in the event of an asthma episode.
    "Asthma episode emergency response protocol" means a 
procedure to provide assistance to a pupil experiencing 
symptoms of wheezing, coughing, shortness of breath, chest 
tightness, or breathing difficulty.
    "Asthma inhaler" means a quick reliever asthma inhaler. 
    "Epinephrine auto-injector" means a single-use device used 
for the automatic injection of a pre-measured dose of 
epinephrine into the human body.

    "Epinephrine  injector" includes an auto-injector approved 
by the United States Food and Drug Administration for the 
administration of epinephrine and a pre-filled syringe 
approved by the United States Food and Drug Administration and 
used for the administration of epinephrine that contains a 
pre-measured dose of epinephrine that is equivalent to the 
dosages used in an auto-injector. 
    "Asthma medication" means a medicine, prescribed by (i) a 
physician
licensed to practice medicine in all its branches,

(ii) a licensed physician assistant with prescriptive 
authority, or (iii) a licensed advanced practice registered
 
nurse with prescriptive authority
for a pupil that pertains to 
the pupil's
asthma and that has an individual prescription 
label.

    "Opioid antagonist" means a drug that binds to opioid 
receptors and blocks or inhibits the effect of opioids acting 
on those receptors, including, but not limited to, naloxone 
hydrochloride or any other similarly acting drug approved by 
the U.S. Food and Drug Administration. 
    "School nurse" means a registered nurse working in a school 
with or without licensure endorsed in school nursing. 
    "Self-administration" means a pupil's discretionary use of 
his or
her prescribed asthma medication or epinephrine injector 
auto-injector.

    "Self-carry" means a pupil's ability to carry his or her 
prescribed asthma medication or epinephrine injector 
auto-injector.
    "Standing protocol" may be issued by (i) a physician 
licensed to practice medicine in all its branches, (ii) a 
licensed physician assistant with prescriptive authority, or 
(iii) a licensed advanced practice registered nurse with 
prescriptive authority. 
    "Trained personnel" means any school employee or volunteer 
personnel authorized in Sections 10-22.34, 10-22.34a, and 
10-22.34b of this Code who has completed training under 
subsection (g) of this Section to recognize and respond to 
anaphylaxis.
    "Undesignated epinephrine injector auto-injector" means an 
epinephrine injector auto-injector prescribed in the name of a 
school district, public school, or nonpublic school. 
    (b) A school, whether public or nonpublic, must permit the

self-administration and self-carry of asthma
medication by a 
pupil with asthma or the self-administration and self-carry of 
an epinephrine injector auto-injector by a pupil, provided 
that:

        (1) the parents or
guardians of the pupil provide to 
    the school (i) written
authorization from the parents or 
    guardians for (A) the self-administration and self-carry 
    of asthma medication or (B)  the self-carry of asthma 
    medication or (ii) for (A) the self-administration and 
    self-carry of an epinephrine injector auto-injector or (B) 
    the self-carry of an epinephrine injector auto-injector, 
    written authorization from the pupil's physician, 
    physician assistant, or advanced practice registered 
    nurse; and

        (2) the
parents or guardians of the pupil provide to 
    the school (i) the prescription label, which must contain 
    the name of the asthma medication, the prescribed dosage, 
    and the time at which or circumstances under which the 
    asthma medication is to be administered, or (ii) for the 
    self-administration or self-carry of an epinephrine 
    injector auto-injector, a
written
statement from the 
    pupil's physician, physician assistant, or advanced 
    practice registered
 nurse containing
the following 
    information:

            (A) the name and purpose of the epinephrine 
        injector auto-injector;

            (B) the prescribed dosage; and

            (C) the time or times at which or the special 
        circumstances
under which the epinephrine injector 
        auto-injector is to be administered.

The information provided shall be kept on file in the office of 
the school
nurse or,
in the absence of a school nurse, the 
school's administrator.

    (b-5)   A school district, public school, or nonpublic school 
may authorize the provision of a student-specific or 
undesignated epinephrine injector auto-injector to a student 
or any personnel authorized under a student's Individual Health 
Care Action Plan, Illinois Food Allergy Emergency Action Plan 
and Treatment Authorization Form, or plan pursuant to Section 
504 of the federal Rehabilitation Act of 1973 to administer an 
epinephrine injector auto-injector to the student, that meets 
the student's prescription on file.
    (b-10)  The school district, public school, or nonpublic 
school may authorize a school nurse or trained personnel to do 
the following: (i) provide an undesignated epinephrine 
injector auto-injector to a student for self-administration 
only or any personnel authorized under a student's Individual 
Health Care Action Plan, Illinois Food Allergy Emergency Action 
Plan and Treatment Authorization Form, or plan pursuant to 
Section 504 of the federal Rehabilitation Act of 1973 to 
administer to the student, that meets the student's 
prescription on file; (ii) administer an undesignated 
epinephrine injector auto-injector that meets the prescription 
on file to any student who has an Individual Health Care Action 
Plan, Illinois Food Allergy Emergency Action Plan and Treatment 
Authorization Form, or plan pursuant to Section 504 of the 
federal Rehabilitation Act of 1973 that authorizes the use of 
an epinephrine injector auto-injector; (iii) administer an 
undesignated epinephrine injector auto-injector to any person 
that the school nurse or trained personnel in good faith 
believes is having an anaphylactic reaction; and (iv) 
administer an opioid antagonist to any person that the school 
nurse or trained personnel in good faith believes is having an 
opioid overdose. 
    (c) The school district, public school, or nonpublic school 
must inform the parents or
guardians of the
pupil, in writing, 
that the school district, public school, or nonpublic school 
and its
employees and
agents, including a physician, physician 
assistant, or advanced practice registered nurse providing 
standing protocol or prescription for school epinephrine 
injectors auto-injectors,
are to incur no liability or 
professional discipline, except for willful and wanton 
conduct, as a result
of any injury arising from the

administration of asthma medication, an epinephrine injector 
auto-injector, or an opioid antagonist regardless of whether 
authorization was given by the pupil's parents or guardians or 
by the pupil's physician, physician assistant, or advanced 
practice registered nurse.  The parents or guardians
of the 
pupil must sign a statement acknowledging that the school 
district, public school,
or nonpublic school and its employees 
and agents are to incur no liability, except for willful and 
wanton
conduct, as a result of any injury arising
from the

administration of asthma medication, an epinephrine injector 
auto-injector, or an opioid antagonist regardless of whether 
authorization was given by the pupil's parents or guardians or 
by the pupil's physician, physician assistant, or advanced 
practice registered nurse and that the parents or
guardians 
must indemnify and hold harmless the school district, public 
school, or nonpublic
school and
its
employees and agents 
against any claims, except a claim based on willful and
wanton 
conduct, arising out of the
administration of asthma 
medication, an epinephrine injector auto-injector, or an 
opioid antagonist regardless of whether authorization was 
given by the pupil's parents or guardians or by the pupil's 
physician, physician assistant, or advanced practice 
registered nurse.
    (c-5) When a school nurse or trained personnel administers 
an undesignated epinephrine injector auto-injector to a person 
whom the school  nurse or trained personnel in good faith 
believes is having an anaphylactic reaction or administers an 
opioid antagonist to a person whom the school nurse or trained 
personnel in good faith believes is having an opioid overdose, 
notwithstanding the lack of notice to the parents or guardians 
of the pupil or the absence of the parents or guardians signed 
statement acknowledging no liability, except for willful and 
wanton conduct, the school district, public school, or 
nonpublic school and its employees and agents, and a physician, 
a physician assistant, or an advanced practice registered  nurse 
providing standing protocol or prescription for undesignated 
epinephrine injectors auto-injectors, are to incur no 
liability or professional discipline, except for willful and 
wanton conduct, as a result of any injury arising from the use 
of an undesignated epinephrine injector auto-injector or the 
use of an opioid antagonist regardless of whether authorization 
was given by the pupil's parents or guardians or by the pupil's 
physician, physician assistant, or advanced practice 
registered nurse.

    (d) The permission for self-administration and self-carry 
of asthma medication or the self-administration and self-carry 
of an epinephrine injector auto-injector is effective
for the 
school year for which it is granted and shall be renewed each

subsequent school year upon fulfillment of the requirements of 
this
Section.

    (e) Provided that the requirements of this Section are 
fulfilled, a
pupil with asthma may self-administer and 
self-carry his or her asthma medication or a pupil may 
self-administer and self-carry an epinephrine injector 
auto-injector (i) while in
school, (ii) while at a 
school-sponsored activity, (iii) while under the
supervision 
of
school personnel, or (iv) before or after normal school 
activities, such
as while in before-school or after-school care 
on school-operated
property or while being transported on a 
school bus.

    (e-5) Provided that the requirements of this Section are 
fulfilled, a school nurse or trained personnel may administer 
an undesignated epinephrine injector auto-injector to any 
person whom the school nurse or trained personnel in good faith 
believes to be having an anaphylactic reaction (i) while in 
school, (ii) while at a school-sponsored activity, (iii) while 
under the supervision of school personnel, or (iv) before or 
after normal school activities, such
as while in before-school 
or after-school care on school-operated property or while being 
transported on a school bus.  A school nurse or trained 
personnel may carry undesignated epinephrine injectors 
auto-injectors on his or her person while in school or at a 
school-sponsored activity. 
    (e-10)  Provided that the requirements of this Section are 
fulfilled, a school nurse or trained personnel may administer 
an opioid antagonist to any person whom the school nurse or 
trained personnel in good faith believes to be having an opioid 
overdose (i) while in school, (ii) while at a school-sponsored 
activity, (iii) while under the supervision of school 
personnel, or (iv) before or after normal school activities, 
such as while in before-school or after-school care on 
school-operated property.  A school nurse or trained personnel 
may carry an opioid antagonist on their person while in school 
or at a school-sponsored activity. 
    (f) The school district, public school, or nonpublic school 
may maintain a supply of undesignated epinephrine injectors 
auto-injectors in any secure location  that is accessible 
before, during, and after school where an allergic person is 
most at risk, including, but not limited to, classrooms and 
lunchrooms. A physician, a physician assistant who has been 
delegated prescriptive authority in accordance with Section 
7.5 of the Physician Assistant Practice Act of 1987, or an 
advanced practice registered nurse who has been delegated 
prescriptive authority in accordance with Section 65-40 of the 
Nurse Practice Act may prescribe undesignated epinephrine 
injectors auto-injectors in the name of the school district, 
public school, or nonpublic school to be maintained for use 
when necessary. Any supply of epinephrine injectors 
auto-injectors shall be maintained in accordance with the 
manufacturer's instructions.
    The school district, public school, or nonpublic school may 
maintain a supply of an opioid antagonist in any secure 
location where an individual may have an opioid overdose.  A 
health care professional who has been delegated prescriptive 
authority for opioid antagonists in accordance with Section 
5-23 of the Alcoholism and Other Drug Abuse and Dependency Act 
may prescribe opioid antagonists in the name of the school 
district, public school, or nonpublic school, to be maintained 
for use when necessary.  Any supply of opioid antagonists shall 
be maintained in accordance with the manufacturer's 
instructions. 
    (f-3)  Whichever entity initiates the process of obtaining 
undesignated epinephrine injectors auto-injectors and 
providing training to personnel for carrying and administering 
undesignated epinephrine injectors auto-injectors shall pay 
for the costs of the undesignated epinephrine injectors 
auto-injectors.
    (f-5) Upon any administration of an epinephrine injector 
auto-injector, a school district, public school, or nonpublic 
school must immediately activate the EMS system and notify the 
student's parent, guardian, or emergency contact, if known.
    Upon any administration of an opioid antagonist, a school 
district, public school, or nonpublic school must immediately 
activate the EMS system and notify the student's parent, 
guardian, or emergency contact, if known. 
    (f-10) Within 24 hours of the administration of an 
undesignated epinephrine injector auto-injector, a school 
district, public school, or nonpublic school must notify the 
physician, physician assistant, or advanced practice 
registered nurse who provided the standing protocol or 
prescription for the undesignated epinephrine injector 
auto-injector of its use. 
    Within 24 hours after the administration of an opioid 
antagonist, a school district, public school, or nonpublic 
school must notify the health care professional who provided 
the prescription for the opioid antagonist of its use. 
    (g) Prior to the administration of an undesignated 
epinephrine injector auto-injector, trained personnel must 
submit to their school's administration proof of completion of 
a training curriculum to recognize and respond to anaphylaxis 
that meets the requirements of subsection (h) of this Section.  
Training must be completed annually. The school district, 
public school, or nonpublic school must maintain records 
related to the training curriculum and trained personnel.
    Prior to the administration of an opioid antagonist, 
trained personnel must submit to their school's administration 
proof of completion of a training curriculum to recognize and 
respond to an opioid overdose, which curriculum must meet the 
requirements of subsection (h-5) of this Section.  Training must 
be completed annually.  Trained personnel must also submit to 
the school's administration proof of cardiopulmonary 
resuscitation and automated external defibrillator 
certification.  The school district, public school, or 
nonpublic school must maintain records relating to the training 
curriculum and the trained personnel. 
    (h) A training curriculum to recognize and respond to 
anaphylaxis, including the administration of an undesignated 
epinephrine injector auto-injector, may be conducted online or 
in person.
    Training shall include, but is not limited to:
        (1)  how to recognize signs and symptoms of an allergic 
    reaction, including anaphylaxis;
        (2) how to administer an epinephrine injector 
    auto-injector; and
        (3)  a test demonstrating competency of the knowledge 
    required to recognize anaphylaxis and administer an 
    epinephrine injector auto-injector.
    Training may also include, but is not limited to:
        (A)  a review of high-risk areas within a school and its 
    related facilities;
        (B)  steps to take to prevent exposure to allergens;
        (C)  emergency follow-up procedures;
        (D)  how to respond to a student with a known allergy, 
    as well as a student with a previously unknown allergy; and
        (E)  other criteria as determined in rules adopted 
    pursuant to this Section.
    In consultation with statewide professional organizations 
representing physicians licensed to practice medicine in all of 
its branches, registered nurses, and school nurses, the State 
Board of Education shall make available resource materials 
consistent with criteria in this subsection (h) for educating 
trained personnel to recognize and respond to anaphylaxis.  The 
State Board may take into consideration the curriculum on this 
subject developed by other states, as well as any other 
curricular materials suggested by medical experts and other 
groups that work on life-threatening allergy issues. The State 
Board is not required to create new resource materials.  The 
State Board shall make these resource materials available on 
its Internet website.
    (h-5)  A training curriculum to recognize and respond to an 
opioid overdose, including the administration of an opioid 
antagonist, may be conducted online or in person.  The training 
must comply with any training requirements under Section 5-23 
of the Alcoholism and Other Drug Abuse and Dependency Act and 
the corresponding rules.  It must include, but is not limited 
to:
        (1) how to recognize symptoms of an opioid overdose;
        (2) information on drug overdose prevention and 
    recognition;
        (3) how to perform rescue breathing and resuscitation;
        (4) how to respond to an emergency involving an opioid 
    overdose;
        (5) opioid antagonist dosage and administration;
        (6) the importance of calling 911;
        (7) care for the overdose victim after administration 
    of the overdose antagonist;
        (8) a test demonstrating competency of the knowledge 
    required to recognize an opioid overdose and administer a 
    dose of an opioid antagonist; and
        (9) other criteria as determined in rules adopted 
    pursuant to this Section. 
    (i) Within 3 days after the administration of an 
undesignated epinephrine injector auto-injector by a school 
nurse, trained personnel, or a student at a school or 
school-sponsored activity, the school must report to the State 
Board of Education in a form and manner prescribed by the State 
Board the following information:
        (1) age and type of person receiving epinephrine 
    (student, staff, visitor);
        (2) any previously known diagnosis of a severe allergy;
        (3) trigger that precipitated allergic episode;
        (4) location where symptoms developed;
        (5) number of doses administered;
        (6) type of person administering epinephrine (school 
    nurse, trained personnel, student); and
        (7)  any other information required by the State Board.
    If a school district, public school, or nonpublic school 
maintains or has an independent contractor providing 
transportation to students who maintains a supply of 
undesignated epinephrine injectors auto-injectors, then the 
school district, public school, or nonpublic school must report 
that information to the State Board of Education upon adoption 
or change of the policy of the school district, public school, 
nonpublic school, or independent contractor,  in a manner as 
prescribed by the State Board.  The report must include the 
number of undesignated epinephrine injectors auto-injectors in 
supply.
    (i-5) Within 3 days after the administration of an opioid 
antagonist by a school nurse or trained personnel, the school 
must report to the State Board of Education, in a form and 
manner prescribed by the State Board, the following 
information:
        (1) the age and type of person receiving the opioid 
    antagonist (student, staff, or visitor);
        (2) the location where symptoms developed;
        (3) the type of person administering the opioid 
    antagonist (school nurse or trained personnel); and
        (4) any other information required by the State Board. 
    (j) By October 1, 2015 and every year thereafter, the State  
Board of Education shall submit a report to the General 
Assembly identifying the frequency and circumstances of 
epinephrine administration during the preceding academic year.  
Beginning with the 2017 report, the report shall also contain 
information on which school districts, public schools, and 
nonpublic schools maintain or have independent contractors 
providing transportation to students who maintain a supply of 
undesignated epinephrine injectors auto-injectors. This report 
shall be published on the State Board's Internet website on the 
date the report is delivered to the General Assembly.
    (j-5) Annually, each school district, public school, 
charter school, or nonpublic school shall request an asthma 
action plan from the parents or guardians of a pupil with 
asthma. If provided, the asthma action plan must be kept on 
file in the office of the school nurse or, in the absence of a 
school nurse, the school administrator. Copies of the asthma 
action plan may be distributed to appropriate school staff who 
interact with the pupil on a regular basis, and, if applicable, 
may be attached to the pupil's federal Section 504 plan or 
individualized education program plan.
    (j-10) To assist schools with emergency response 
procedures for asthma, the State Board of Education, in 
consultation with statewide professional organizations with 
expertise in asthma management and a statewide organization 
representing school administrators, shall develop a model 
asthma episode emergency response protocol before September 1, 
2016. Each school district, charter school, and nonpublic 
school shall adopt an asthma episode emergency response 
protocol before January 1, 2017 that includes all of the 
components of the State Board's model protocol.
    (j-15) Every 2 years, school personnel who work with pupils 
shall complete an in-person or online training program on the 
management of asthma, the prevention of asthma symptoms, and 
emergency response in the school setting.  In consultation with 
statewide professional organizations with expertise in asthma 
management, the State Board of Education shall make available 
resource materials for educating school personnel about asthma 
and emergency response in the school setting.
    (j-20) On or before October 1, 2016 and every year 
thereafter, the State Board of Education shall submit a report 
to the General Assembly and the Department of Public Health 
identifying the frequency and circumstances of opioid 
antagonist administration during the preceding academic year.  
This report shall be published on the State Board's Internet 
website on the date the report is delivered to the General 
Assembly. 
    (k) The State Board of Education may adopt rules necessary 
to implement this Section. 
    (l)  Nothing in this Section shall limit the amount of 
epinephrine injectors auto-injectors that any type of school or 
student may carry or maintain a supply of.
(Source: P.A. 99-173, eff. 7-29-15; 99-480, eff. 9-9-15; 
99-642, eff. 7-28-16; 99-711, eff. 1-1-17; 99-843, eff. 
8-19-16; 100-201, eff. 8-18-17; 100-513, eff. 1-1-18.)

 
    Section 10. The Epinephrine Auto-Injector Act is amended  by 
changing Sections 1, 5, 10, 15, and 20 as follows:
 
    (410 ILCS 27/1)

    Sec. 1. Short title. This Act may be cited as the 
Epinephrine Injector Auto-Injector Act.

(Source: P.A. 99-711, eff. 1-1-17.)
 
    (410 ILCS 27/5)
    Sec. 5. Definitions. As used in this Act:
    "Administer" means to directly apply an epinephrine 
injector auto-injector to the body of an individual.
    "Authorized entity" means any entity or organization, 
other than a school covered under Section 22-30 of the School 
Code, in connection with or at which allergens capable of 
causing anaphylaxis may be present, including, but not limited 
to, independent contractors who provide student transportation 
to schools, recreation camps, colleges and universities, day 
care facilities, youth sports leagues, amusement parks, 
restaurants, sports arenas, and places of employment. The 
Department shall, by rule, determine what constitutes a day 
care facility under this definition.
    "Department" means the Department of Public Health.
    "Epinephrine  injector" includes an auto-injector approved 
by the United States Food and Drug Administration for the 
administration of epinephrine and a pre-filled syringe 
approved by the United States Food and Drug Administration and 
used for the administration of epinephrine that contains a 
pre-measured dose of epinephrine that is equivalent to the 
dosages used in an auto-injector. 
    "Epinephrine auto-injector" means a single-use device used 
for the automatic injection of a pre-measured dose of 
epinephrine into the human body.
    "Health care practitioner" means a physician licensed to 
practice medicine in all its branches under the Medical 
Practice Act of 1987, a physician assistant under the Physician 
Assistant Practice Act of 1987 with prescriptive authority, or 
an advanced practice registered nurse with prescribing 
authority under Article 65 of the Nurse Practice Act.
    "Pharmacist" has the meaning given to that term under 
subsection (k-5) of Section 3 of the Pharmacy Practice Act.
    "Undesignated epinephrine injector auto-injector" means an 
epinephrine injector auto-injector prescribed in the name of an 
authorized entity.

(Source: P.A. 99-711, eff. 1-1-17; 100-513, eff. 1-1-18.)
 
    (410 ILCS 27/10)

    Sec. 10. Prescription to authorized entity; use; training.
    (a) A health care practitioner may prescribe epinephrine 
injectors auto-injectors in the name of an authorized entity 
for use in accordance with this Act, and pharmacists and health 
care practitioners may dispense epinephrine injectors 
auto-injectors pursuant to a prescription issued in the name of 
an authorized entity. Such prescriptions shall be valid for a 
period of 2 years.
    (b) An authorized entity may acquire and stock a supply of 
undesignated epinephrine injectors auto-injectors pursuant to 
a prescription issued under subsection (a) of this Section. 
Such undesignated epinephrine injectors auto-injectors shall 
be stored in a location readily accessible in an emergency and 
in accordance with the instructions for use of the epinephrine 
injectors auto-injectors. The Department may establish any 
additional requirements an authorized entity must follow under 
this Act.
    (c) An employee or agent of an authorized entity or other 
individual who has completed training under subsection (d) of 
this Section may:
        (1) provide an epinephrine injector auto-injector to 
    any individual on the property of the authorized entity 
    whom the employee, agent, or other individual believes in 
    good faith is experiencing anaphylaxis, or to the parent, 
    guardian, or caregiver of such individual, for immediate 
    administration, regardless of whether the individual has a 
    prescription for an epinephrine injector auto-injector or 
    has previously been diagnosed with an allergy; or
        (2) administer an epinephrine injector auto-injector 
    to any individual on the property of the authorized entity 
    whom the employee, agent, or other individual believes in 
    good faith is experiencing anaphylaxis, regardless of 
    whether the individual has a prescription for an 
    epinephrine injector auto-injector or has previously been 
    diagnosed with an allergy.
    (d) An employee, agent, or other individual authorized must 
complete an anaphylaxis training program before he or she is 
able to provide or administer an epinephrine injector 
auto-injector under this Section. Such training shall be valid 
for a period of 2 years and shall be conducted by a nationally 
recognized organization experienced in training laypersons in 
emergency health treatment. The Department shall include links 
to training providers' websites on its website.
    Training shall include, but is not limited to:
        (1)  how to recognize signs and symptoms of an allergic 
    reaction, including anaphylaxis;
        (2)  how to administer an epinephrine injector 
    auto-injector; and
        (3) a test demonstrating competency of the knowledge 
    required to recognize anaphylaxis and administer an 
    epinephrine injector auto-injector.
    Training may also include, but is not limited to:
        (A) a review of high-risk areas on the authorized 
    entity's property and its related facilities;
        (B) steps to take to prevent exposure to allergens;
        (C) emergency follow-up procedures; and
        (D) other criteria as determined in rules adopted 
    pursuant to this Act.
    Training may be conducted either online or in person.  The 
Department shall approve training programs and list permitted 
training programs on the Department's Internet website.

(Source: P.A. 99-711, eff. 1-1-17.)
 
    (410 ILCS 27/15)

    Sec. 15. Costs.  Whichever entity initiates the process of 
obtaining undesignated epinephrine injectors auto-injectors 
and providing training to personnel for carrying and 
administering undesignated epinephrine injectors 
auto-injectors shall pay for the costs of the undesignated 
epinephrine injectors auto-injectors.

(Source: P.A. 99-711, eff. 1-1-17.)
 
    (410 ILCS 27/20)

    Sec. 20. Limitations.  The use of an undesignated 
epinephrine injector auto-injector in accordance with the 
requirements of this Act does not constitute the practice of 
medicine or any other profession that requires medical 
licensure.
    Nothing in this Act shall limit the amount of epinephrine 
injectors auto-injectors that an authorized entity or 
individual may carry or maintain a supply of.

(Source: P.A. 99-711, eff. 1-1-17.)
 
    Section 15. The Illinois Food, Drug and Cosmetic Act is 
amended  by changing Section 3.21 as follows:
 


    (410 ILCS 620/3.21)  (from Ch. 56 1/2, par. 503.21)



    Sec. 3.21. Except as authorized by this Act, the Illinois 
Controlled Substances
Act, the Pharmacy Practice Act, the 
Dental Practice Act, the Medical
Practice Act of 1987, the 
Veterinary Medicine and Surgery Practice Act of
2004, the 
Podiatric Medical Practice Act of 1987, Section 22-30 of the 
School Code, Section 40 of the State Police Act, Section 10.19 
of the Illinois Police Training Act, or the Epinephrine 
Injector Auto-Injector Act, to sell or dispense a
prescription 
drug without a prescription.

(Source: P.A. 99-78, eff. 7-20-15; 99-711, eff. 1-1-17.)



Effective Date:  1/1/2019